Latest Insider Transactions at Albireo Pharma, Inc. (ALBO)
This section provides a real-time view of insider transactions for Albireo Pharma, Inc. (ALBO). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of ALBIREO PHARMA, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of ALBIREO PHARMA, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 01
2021
|
Jason Duncan Chief Legal Officer and GC |
BUY
Exercise of conversion of derivative security
|
Direct |
300
+3.42%
|
$7,200
$24.04 P/Share
|
|
Mar 31
2021
|
Jason Duncan Chief Legal Officer and GC |
SELL
Open market or private sale
|
Direct |
1,426
-14.87%
|
$49,910
$35.04 P/Share
|
|
Mar 29
2021
|
Pamela Stephenson Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
422
-1.54%
|
$14,348
$34.02 P/Share
|
|
Mar 03
2021
|
Jan Mattsson Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
400
-1.05%
|
$14,400
$36.2 P/Share
|
|
Mar 02
2021
|
Jan Mattsson Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
15,770
-10.45%
|
$567,720
$36.59 P/Share
|
|
Mar 01
2021
|
Jan Mattsson Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
15,300
-22.16%
|
$566,100
$37.45 P/Share
|
|
Mar 01
2021
|
Jan Mattsson Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
39,330
+36.29%
|
$39,330
$1.0 P/Share
|
|
Jan 22
2021
|
Patrick Taylor Horn Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
110
-1.11%
|
$3,740
$34.62 P/Share
|
|
Jan 22
2021
|
Jason Duncan Chief Legal Officer and GC |
SELL
Open market or private sale
|
Direct |
110
-1.17%
|
$3,740
$34.62 P/Share
|
|
Jan 21
2021
|
Ronald Harold Wilfred Cooper President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
48,700
+46.31%
|
-
|
|
Jan 21
2021
|
Pamela Stephenson Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,500
+16.71%
|
-
|
|
Jan 21
2021
|
Patrick Taylor Horn Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,500
+35.63%
|
-
|
|
Jan 21
2021
|
Michelle Graham Chief Human Resources Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,500
+50.0%
|
-
|
|
Jan 21
2021
|
Martha J. Carter Chief Regulatory Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,500
+50.0%
|
-
|
|
Jan 21
2021
|
Jan Mattsson Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,500
+15.62%
|
-
|
|
Jan 21
2021
|
Jason Duncan Chief Legal Officer and GC |
BUY
Grant, award, or other acquisition
|
Direct |
5,500
+36.81%
|
-
|
|
Jan 21
2021
|
Simon N.R. Harford CFO and Treasurer |
BUY
Grant, award, or other acquisition
|
Direct |
5,500
+35.22%
|
-
|
|
Jan 11
2021
|
Simon N.R. Harford CFO and Treasurer |
SELL
Open market or private sale
|
Direct |
110
-2.33%
|
$4,070
$37.33 P/Share
|
|
Dec 28
2020
|
Pamela Stephenson Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
460
-2.06%
|
$17,940
$39.07 P/Share
|
|
Oct 22
2020
|
Jason Duncan Chief Legal Officer and GC |
SELL
Open market or private sale
|
Direct |
89
-2.3%
|
$3,026
$34.71 P/Share
|
|
Oct 22
2020
|
Patrick Taylor Horn Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
89
-2.03%
|
$3,026
$34.55 P/Share
|
|
Oct 12
2020
|
Simon N.R. Harford CFO and Treasurer |
SELL
Open market or private sale
|
Direct |
90
-1.91%
|
$3,330
$37.3 P/Share
|
|
Sep 14
2020
|
Perceptive Advisors LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
400,000
+14.49%
|
$16,000,000
$40.0 P/Share
|
|
Feb 03
2020
|
Perceptive Advisors LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
255,809
+11.54%
|
$5,371,989
$21.0 P/Share
|
|
Jan 25
2018
|
Perceptive Advisors LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
275,000
+14.71%
|
$9,075,000
$33.0 P/Share
|
|
Dec 01
2017
|
Astrazeneca PLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
500,000
-49.6%
|
$10,500,000
$21.4 P/Share
|